Literature DB >> 25170322

Shedding the epilepsy comorbidity in Alzheimer's disease.

Elizabeth M Powell.   

Abstract

Entities:  

Year:  2014        PMID： 25170322      PMCID： PMC4120394          DOI： 10.5698/1535-7597-14.4.211

Source DB:  PubMed          Journal:  Epilepsy Curr        ISSN： 1535-7511            Impact factor:   7.500


× No keyword cloud information.
  7 in total

1.  The disintegrin/metalloproteinase ADAM10 is essential for the establishment of the brain cortex.

Authors:  Ellen Jorissen; Johannes Prox; Christian Bernreuther; Silvio Weber; Ralf Schwanbeck; Lutgarde Serneels; An Snellinx; Katleen Craessaerts; Amantha Thathiah; Ina Tesseur; Udo Bartsch; Gisela Weskamp; Carl P Blobel; Markus Glatzel; Bart De Strooper; Paul Saftig
Journal:  J Neurosci       Date:  2010-04-07       Impact factor: 6.167

2.  ADAM10 missense mutations potentiate β-amyloid accumulation by impairing prodomain chaperone function.

Authors:  Jaehong Suh; Se Hoon Choi; Donna M Romano; Moira A Gannon; Andrea N Lesinski; Doo Yeon Kim; Rudolph E Tanzi
Journal:  Neuron       Date:  2013-09-19       Impact factor: 17.173

3.  Postnatal disruption of the disintegrin/metalloproteinase ADAM10 in brain causes epileptic seizures, learning deficits, altered spine morphology, and defective synaptic functions.

Authors:  Johannes Prox; Christian Bernreuther; Hermann Altmeppen; Jasper Grendel; Markus Glatzel; Rudi D'Hooge; Stijn Stroobants; Tariq Ahmed; Detlef Balschun; Michael Willem; Sven Lammich; Dirk Isbrandt; Michaela Schweizer; Katrien Horré; Bart De Strooper; Paul Saftig
Journal:  J Neurosci       Date:  2013-08-07       Impact factor: 6.167

4.  Effects of neuron-specific ADAM10 modulation in an in vivo model of acute excitotoxic stress.

Authors:  A B Clement; R Hanstein; A Schröder; H Nagel; K Endres; F Fahrenholz; C Behl
Journal:  Neuroscience       Date:  2008-01-12       Impact factor: 3.590

5.  The disintegrin/metalloprotease ADAM 10 is essential for Notch signalling but not for alpha-secretase activity in fibroblasts.

Authors:  Dieter Hartmann; Bart de Strooper; Lutgarde Serneels; Katleen Craessaerts; An Herreman; Wim Annaert; Lieve Umans; Torben Lübke; Anna Lena Illert; Kurt von Figura; Paul Saftig
Journal:  Hum Mol Genet       Date:  2002-10-01       Impact factor: 6.150

6.  Genetic suppression of transgenic APP rescues Hypersynchronous network activity in a mouse model of Alzeimer's disease.

Authors:  Heather A Born; Ji-Yoen Kim; Ricky R Savjani; Pritam Das; Yuri A Dabaghian; Qinxi Guo; Jong W Yoo; Dorothy R Schuler; John R Cirrito; Hui Zheng; Todd E Golde; Jeffrey L Noebels; Joanna L Jankowsky
Journal:  J Neurosci       Date:  2014-03-12       Impact factor: 6.167

7.  ADAM10 expression and promoter haplotype in Alzheimer's disease.

Authors:  Lynn M Bekris; Franziska Lutz; Gail Li; Douglas R Galasko; Martin R Farlow; Joseph F Quinn; Jeffrey A Kaye; James B Leverenz; Debby W Tsuang; Thomas J Montine; Elaine R Peskind; Chang-En Yu
Journal:  Neurobiol Aging       Date:  2012-05-08       Impact factor: 4.673
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.